Joyce Chan

Director Business Development at Amgen

Speaker

Joyce Chan is a Director of Business Development at Amgen Inc and currently leads global partnering efforts for Amgen’s Cardiovascular, Metabolism, Bone, Nephrology and Neurosciences therapeutic areas. Prior to joining BD, Joyce was a preclinical pharmacologist in the Cardiometabolic therapeutics group, engaged in both large and small molecule translational research for Amgen’s metabolism, dyslipidemia and heart failure programs. Of her most notable contributions, Joyce is a co-inventor of Repatha, the first anti-PCSK9 antibody indicated to reduce the risk of myocardial infarction, stroke and coronary revascularization, and for further LDL-C reduction in heterozygous and homozygous familial hypercholesterolemia; she was also the lead author on the first proof-of-concept publication supporting an anti-PCSK9 pharmacological approach for LDL-C lowering. Prior to Amgen, Joyce held various research roles in the departments of Cardiovascular Research and Pharmacology at Berlex Biosciences (an affiliate of Schering AG) where she engaged in early drug discovery efforts for hypertension, heart failure and dermatology. She has a PhD in Biochemistry from the University of Notre Dame, where her research focused on thrombosis and haemostasis and a BSc in Biochemistry from the University of Waterloo, Canada.